Table 2.

Adverse Events

CTCAE Term	All Grades: No. (% of Patients) (n = 30)	Grades 3+: No. (% of Patiens) (n = 30)
Adverse effects that led to temporary or permanent avelumab discontinuation
Disease progression	19 (63.3)	17 (56.7)
Radiation necrosis	2 (6.7)	2 (6.7)
Thromboembolic event	2 (6.7)	2 (6.7)
Seizure	2 (6.7)	2 (6.7)
COPD exacerbation	1 (3.3)	1 (3.3)
Rash NOS	1 (3.3)	0
Erythema multiform	1 (3.3)	1 (3.3)
Platelet count decreased	1 (3.3)	1 (3.3)
Fever	1 (3.3)	0
Hypotension	1 (3.3)	0
Urinary tract infection	2 (6.7)	2 (6.7)
Fatigue	1 (3.3)	0
Meningitis	1 (3.3)	1 (3.3)
AST elevated	3 (6.7)	0
GGT elevated	3 (6.7)	3 (6.7)
LDH elevated	2 (6.7)	0
ALT elevated	1 (3.3)	1 (3.3)
Alkaline phosphatase increased	1 (3.3)	0
Localized edema	1 (3.3)	1 (3.3)
Pneumatosis intestinalis	1 (3.3)	1 (3.3)
Infusion-related reactions
Fever	5 (16.7)	0
Diarrhea	2 (6.7)	0
Nausea	2 (6.7)	0
Chills	1 (3.3)	0
Headache	1 (3.3)	0
Hypertension	1 (3.3)	0
Vomiting	1 (3.3)	0
Syncope	1 (3.3)	1 (3.3)
Immune-related adverse events
Colitis	2 (6.7)	0
ALT increased	3 (6.7)	1 (3.3)
AST increased	5 (10.0)	0
LDH increased	5 (13.3)	0
GGT increased	4 (6.7)	4 (6.7)
Alkaline phosphatase increased	1 (3.3)	0
Hypophysitis	2 (6.7)	0
Hypothyroidism	2 (6.7)	1 (3.3)
Lipase Increased	1 (3.3)	0
Serum amylase increased	3 (6.7)	1 (3.3)
Mastocytosis	1 (3.3)	0
Rash	1 (3.3)	0